Podium Session
(POD-1) Advanced Prostate Cancer, Testes Cancer & Kidney Cancer

Thursday January 10, 2019 | 13:30 to 14:30
Room: Pier 4&5

Learning Objectives

As a result of attending this session, participants will be able to:

  • understand real-world utilization patterns of surgical castration and Ra223 therapy in the management of advanced prostate cancer
  • appreciate the worse outcome of men with high percent-free PSA at biochemical recurrence after prostatectomy
  • consider the safety of partial orchiectomy in men with small testicular lesions
  • describe the comparative outcome of men with early stage seminoma undergoing radiation versus chemotherapy versus active surveillance
  • appreciate the benefit of using cabozantinib for renal cell carcinoma irrespective of prior immune checkpoint blockade   

Presentations

Surgical castration in the management of metastatic prostate cancer: Current trends in androgen deprivation therapy
Dr. Patrick T. Anderson, Canada
University of Ottawa, The Ottawa Hospital, Ottawa

A high percent-free PSA in the setting of biochemical recurrence after radical prostatectomy is associated with poorer outcomes: A validation study using prospectively collected biobank specimens
Dr. Dixon Teck Sing Woon, Canada
University Health Network, Toronto

Factors associated with treatment completion and survival in patients with metastatic, castration-resistant prostate cancer undergoing radium-223 therapy in Ontario
Sierra Cheng, Canada
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Partial Orchiectomy: A review of the Princess Margaret Cancer Centre experience
Dr. Greg Nason, Canada
University of Toronto, Toronto

Second cancer incidence and competing causes of death in patients with early stage Seminoma: A population-based study comparing radiation therapy versus chemotherapy
Dr. Gaurav Bahl, Canada
University of British Columbia / BC Cancer Agency, Abbotsford

Activity of cabozantinib after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)
Dr. Aly-Khan A. Lalani, Canada
Juravinski Cancer Centre, Burlington

Email: info@cuos.ca
© 2019 CUOS 2019